Day: June 26, 2020

PERSBERICHT: 26 juni 2020, 07:00 CESTMulticenterstudie in de VS toont dat Idylla™ snelle en accurate mutatietesting resultaten mogelijk maakt in diverse laboratoria settingsMechelen, België, 26 juni 2020 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag de publicatie aan in het ‘American Journal of Clinical Pathology’ van een nieuwe multicenterstudie1 geleid door onderzoekers van Dartmouth’s en Dartmouth-Hitchcock’s Norris Cotton Cancer Center (Lebanon, New Hampshire, VS). De studie toonde dat Idylla™, het moleculair diagnostiekplatform van Biocartis, in vergelijking met huidige standaard testing methodes de tijd-tot-resultaat van mutatietesting aanzienlijk kan verbeteren, onafhankelijk van de grootte van het laboratorium.Het nieuwe multicenteronderzoek...

uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour cell staining positivityRoche advances personalised healthcare with development of image analysis algorithms using artificial intelligenceFaster, more accurate diagnoses are critical with non-small cell lung cancer, which accounts for about 85 percent of all lung cancer casesBasel, June 26, 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment...

MONTREAL, June 25, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders held in Montreal, Quebec (“Meeting”).Election of DirectorsEach director nominee listed in the Management Information Circular dated May 26, 2020 (“Circular”) was elected as Director of the Corporation at the Meeting. Shareholders present in person or represented by proxy at the Meeting voted as follows:Appointment of external AuditorsErnst & Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present or represented by proxy, and the directors were...

MONTRÉAL, 25 juin 2020 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX:GUD) (« Knight » ou la « Société ») société pharmaceutique spécialisée panaméricaine (ex. EU) et chef de file a annoncé aujourd’hui les résultats du vote à l’assemblée annuelle des actionnaires tenue à Montréal, Québec (« l’assemblée »).Élection des administrateursChaque candidat au poste d’administrateur figurant sur la circulaire de procuration de la direction de la Société, datée du 26 mai 2020 (la « circulaire »), a été élu en qualité d’administrateur de la Société lors de l’assemblée. Les actionnaires présents en personne ou représentés par procuration à l’assemblée ont voté comme suit :Nomination de l’auditeur externeNomination de Ernst & Young s.r.l./ S.E.N.C.R.L. à titre d’auditeurs externes...

Mexico City, June 25, 2020 (GLOBE NEWSWIRE) — Mexico City, June 25, 2020.- Aeromexico informs that in July it will continue resuming service to destinations where it had suspended due to the effects of COVID-19 and will increase frequencies to cities in which it has maintained its operations.For the following month, Aeromexico will increase its service in the domestic market to almost double the number of flights compared to the previous month, as follows:It will increase frequencies to destinations such as Cancun, Guadalajara, Tijuana, Monterrey, and Merida.It will resume its operations from Mexico City to Huatulco, Zacatecas and Manzanillo, and from Monterrey to Cancun, Queretaro, Chihuahua and Hermosillo.It will launch a new route between Monterrey-Tijuana. For the international market, it expects an operation of almost four times...

LEXINGTON, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its underwritten public offering of 12,506,811 shares of its common stock at a public offering price of $22.00 per share. In the offering, Translate Bio will issue and sell 5,681,819 shares and an existing stockholder, Shire Human Genetic Therapies, Inc. (Shire), a subsidiary of Takeda Pharmaceutical Company Limited, will sell 6,824,992 shares. The gross proceeds to Translate Bio from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Translate Bio, are expected to be approximately $125.0...

VANCOUVER, British Columbia, June 25, 2020 (GLOBE NEWSWIRE) — BC Craft Supply Co. Ltd. (the “Company” or “BC Craft”) (CSE: CRFT) (FSE: ZZD1) is pleased to announce that it has closed a non-brokered private placement for a total of 34,209,639 units (the “Units”) of the Company at a price of $0.05 per Unit for gross aggregate proceeds of $1,710,482 (the “Private Placement”). Each Unit consists of one (1) common share (each a “Common Share”) and one-half (1/2) of one transferable common share purchase warrant (with two half warrants being  a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one (1) additional Common Share per Warrant at a price of $0.10 for a period of eighteen (18) months from closing.The Warrants are subject to an accelerated expiry whereby should the 20-day volume weight average price of the...

Toronto, Ontario, June 25, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tree of Knowledge International Corp. (CSE: TOKI) (the “Company” or “TOKI”) is pleased to announce that further to its press release dated June 19, 2020, the Company’s principal regulator, the Ontario Securities Commission, has accepted the Company’s application for, and granted, a management cease trade order (the “MCTO”). The application for the MCTO was made by the Company due to a delay in the filing of its audited annual financial statements, accompanying management discussion and analysis and related CEO and CFO certifications for the year ended December 31, 2019 (the “Annual Filings”).The Company is actively working with its auditors to file the Annual Filings, which the Company expects to be completed in due course.On...

GUADALAJARA, Mexico, June 25, 2020 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (the “Company” or “GAP”) announced today that it successfully completed the issuance of 42 million long-term bond certificates in Mexico (Certificados Bursátiles) at a nominal value of Ps. 100 each (one hundred pesos 00/100), for a total value of Ps. 4.2 billion, issued jointly. The amount of the issuance was up to Ps. 3.0 billion with a greenshoe option of up to 40%, which was reached at the closing of the issuance.The bond certificates were issued in accordance with the following terms:6.02 million bond certificates were issued under the ticker symbol “GAP20-2”, at a nominal value of Ps. 100 (one hundred pesos 00/100) each, for a total value of Ps. 602 million (six hundred and two million pesos 00/100)....

FINTEPLA® significantly and substantially reduced convulsive seizure frequency in patients whose seizures were not adequately controlled on other medications, as observed in two phase 3 placebo-controlled clinical trialsCommercial launch planned for July 2020Zogenix to host an investor call tomorrow, June 26, at 8:30 AM ET / 5:30 AM PTEMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved FINTEPLA® (fenfluramine) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. FINTEPLA will be launched through a restricted distribution program, called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS)...